PMC:7205724 / 0-307
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1 | 30-38 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 3 | 252-259 | Species | denotes | patient | Tax:9606 |
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T1 | 132-147 | Body_part | denotes | immunoglobulins | http://purl.org/sig/ont/fma/fma62871 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T1 | 30-38 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T1 | 89-113 | Chemical | denotes | immunosuppressive agents | http://purl.obolibrary.org/obo/CHEBI_35705 |
| T2 | 153-168 | Chemical | denotes | corticosteroids | http://purl.obolibrary.org/obo/CHEBI_50858 |
| T3 | 221-236 | Chemical | denotes | corticosteroids | http://purl.obolibrary.org/obo/CHEBI_50858 |
| T4 | 284-299 | Chemical | denotes | corticosteroids | http://purl.obolibrary.org/obo/CHEBI_50858 |
LitCovid-sample-MedDRA
| Id | Subject | Object | Predicate | Lexical cue | meddra_id |
|---|---|---|---|---|---|
| T1 | 132-147 | http://purl.bioontology.org/ontology/MEDDRA/10022891 | denotes | immunoglobulins | http://purl.bioontology.org/ontology/MEDDRA/10021496 |
LitCovid-sample-PD-IDO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 89-106 | http://purl.obolibrary.org/obo/IDO_0000610 | denotes | immunosuppressive |
LitCovid-sample-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T1 | 153-168 | Chemical | denotes | corticosteroids | http://purl.obolibrary.org/obo/CHEBI_50858 |
| T2 | 221-236 | Chemical | denotes | corticosteroids | http://purl.obolibrary.org/obo/CHEBI_50858 |
| T3 | 284-299 | Chemical | denotes | corticosteroids | http://purl.obolibrary.org/obo/CHEBI_50858 |
LitCovid-sample-PD-NCBITaxon
| Id | Subject | Object | Predicate | Lexical cue | ncbi_taxonomy_id |
|---|---|---|---|---|---|
| T1 | 30-38 | Species | denotes | COVID-19 | NCBItxid:2697049 |
LitCovid-sample-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-39 | Sentence | denotes | Towards treatment planning of COVID-19: |
| T2 | 40-114 | Sentence | denotes | Rationale and hypothesis for the use of multiple immunosuppressive agents: |
| T3 | 115-168 | Sentence | denotes | Anti-antibodies, immunoglobulins, and corticosteroids |
| T4 | 170-180 | Sentence | denotes | Highlights |
| T5 | 181-269 | Sentence | denotes | • IVIG, combined with moderate-dose of corticosteroids, might improve patient outcomes. |
LitCovid-sample-Pubtator
| Id | Subject | Object | Predicate | Lexical cue | pubann:denotes |
|---|---|---|---|---|---|
| 1 | 30-38 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 3 | 252-259 | Species | denotes | patient | Tax:9606 |
LitCovid-sample-Enju
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T0 | 0-7 | IN | denotes | Towards |
| T1 | 8-17 | NN | denotes | treatment |
| T2 | 18-26 | NN | denotes | planning |
| T3 | 27-29 | IN | denotes | of |
| T4 | 30-38 | NN | denotes | COVID-19 |
| T5 | 38-39 | -COLON- | denotes | : |
| T6 | 40-49 | NN | denotes | Rationale |
| T7 | 50-53 | CC | denotes | and |
| T8 | 54-64 | NN | denotes | hypothesis |
| T9 | 65-68 | IN | denotes | for |
| T10 | 69-72 | DT | denotes | the |
| T11 | 73-76 | NN | denotes | use |
| T12 | 77-79 | IN | denotes | of |
| T13 | 80-88 | JJ | denotes | multiple |
| T14 | 89-106 | JJ | denotes | immunosuppressive |
| T15 | 107-113 | NNS | denotes | agents |
| T16 | 113-114 | -COLON- | denotes | : |
| T17 | 115-130 | NNS | denotes | Anti-antibodies |
| T18 | 130-131 | -COMMA- | denotes | , |
| T19 | 132-147 | NNS | denotes | immunoglobulins |
| T20 | 147-148 | -COMMA- | denotes | , |
| T21 | 149-152 | CC | denotes | and |
| T22 | 153-168 | NNS | denotes | corticosteroids |
| T23 | 170-180 | NNS | denotes | Highlights |
| T24 | 181-182 | IN | denotes | • |
| T25 | 184-188 | NNP | denotes | IVIG |
| T26 | 188-189 | -COMMA- | denotes | , |
| T27 | 190-198 | VBN | denotes | combined |
| T28 | 199-203 | IN | denotes | with |
| T29 | 204-217 | NN | denotes | moderate-dose |
| T30 | 218-220 | IN | denotes | of |
| T31 | 221-236 | NNS | denotes | corticosteroids |
| T32 | 236-237 | -COMMA- | denotes | , |
| T33 | 238-243 | MD | denotes | might |
| T34 | 244-251 | VB | denotes | improve |
| T35 | 252-259 | NN | denotes | patient |
| T36 | 260-268 | NNS | denotes | outcomes |
| T37 | 270-271 | PDT | denotes | • |
| T38 | 273-276 | DT | denotes | The |
| T39 | 277-280 | NN | denotes | use |
| T40 | 281-283 | IN | denotes | of |
| T41 | 284-299 | NNS | denotes | corticosteroids |
| T42 | 300-305 | MD | denotes | might |
| R0 | T2 | T0 | arg2Of | planning,Towards |
| R1 | T2 | T1 | arg1Of | planning,treatment |
| R2 | T2 | T3 | arg1Of | planning,of |
| R3 | T4 | T3 | arg2Of | COVID-19,of |
| R4 | T2 | T5 | arg1Of | planning,: |
| R5 | T6 | T7 | arg1Of | Rationale,and |
| R6 | T8 | T7 | arg2Of | hypothesis,and |
| R7 | T7 | T9 | arg1Of | and,for |
| R8 | T11 | T9 | arg2Of | use,for |
| R9 | T11 | T10 | arg1Of | use,the |
| R10 | T11 | T12 | arg1Of | use,of |
| R11 | T15 | T12 | arg2Of | agents,of |
| R12 | T15 | T13 | arg1Of | agents,multiple |
| R13 | T15 | T14 | arg1Of | agents,immunosuppressive |
| R14 | T7 | T16 | arg1Of | and,: |
| R15 | T17 | T18 | arg1Of | Anti-antibodies,"," |
| R16 | T19 | T18 | arg2Of | immunoglobulins,"," |
| R17 | T21 | T20 | arg1Of | and,"," |
| R18 | T18 | T21 | arg1Of | ",",and |
| R19 | T22 | T21 | arg2Of | corticosteroids,and |
| R20 | T25 | T24 | arg1Of | IVIG,• |
| R21 | T25 | T26 | arg1Of | IVIG,"," |
| R22 | T25 | T27 | arg2Of | IVIG,combined |
| R23 | T27 | T28 | arg1Of | combined,with |
| R24 | T29 | T28 | arg2Of | moderate-dose,with |
| R25 | T29 | T30 | arg1Of | moderate-dose,of |
| R26 | T31 | T30 | arg2Of | corticosteroids,of |
| R27 | T34 | T32 | arg1Of | improve,"," |
| R28 | T25 | T33 | arg1Of | IVIG,might |
| R29 | T34 | T33 | arg2Of | improve,might |
| R30 | T25 | T34 | arg1Of | IVIG,improve |
| R31 | T36 | T34 | arg2Of | outcomes,improve |
| R32 | T36 | T35 | arg1Of | outcomes,patient |
| R33 | T39 | T37 | arg1Of | use,• |
| R34 | T39 | T38 | arg1Of | use,The |
| R35 | T39 | T40 | arg1Of | use,of |
| R36 | T41 | T40 | arg2Of | corticosteroids,of |
| R37 | T39 | T42 | arg1Of | use,might |
LitCovid-sample-PD-FMA
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T1 | 132-147 | Body_part | denotes | immunoglobulins | http://purl.org/sig/ont/fma/fma62871 |
LitCovid-sample-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T1 | 30-38 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-39 | Sentence | denotes | Towards treatment planning of COVID-19: |
| T2 | 40-114 | Sentence | denotes | Rationale and hypothesis for the use of multiple immunosuppressive agents: |
| T3 | 115-168 | Sentence | denotes | Anti-antibodies, immunoglobulins, and corticosteroids |
| T4 | 170-180 | Sentence | denotes | Highlights |
| T5 | 181-269 | Sentence | denotes | • IVIG, combined with moderate-dose of corticosteroids, might improve patient outcomes. |